Mesoblast Announced Single Intervention With Rexlemestrocel-l Improves Left Ventricular Ejection Fraction at 12 Months, Preceding Long-term Reduction in Major Adverse Cardiovascular Events
July 19, 5:13 AM
Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that treatment of HFrEF patients with rexlemestrocel-L, its allogeneic "off-the-shelf" product candidate for the treatment of chronic heart failure with reduced ejection fraction, resulted in greater improvement in the pre-specified analysis of left ventricular ejecti
Tesla Chair Robyn Denholm Said Co’s EV Sales are Rapidly Rising Off Low Base in Australia and Set to Catch up with Powerwall Sales
July 19, 5:08 AM
-Reuters
https://www.reuters.com/business/autos-transportation/tesla-ev-sales-gaining-momentum-australia-chair-2022-07-19/
TotalEnergies and ADNOC Expand Strategic Alliance
July 19, 5:05 AM
On the occasion of the state visit in Paris of His Highness Sheikh, Mohamed bin Zayed Al Nahyan, President of the United Arab Emirates, TotalEnergies (Paris:TTE) (LSE:TTE) (NYSE: TTE) and Abu Dhabi National Oil Company (ADNOC) have signed a strategic partnership agreement that aims to jointly evaluate new growth opportunities in
Chase Corporation to Acquire NuCera Solutions from SK Capital for $250M
July 19, 5:00 AM
An affiliate of funds advised by SK Capital Partners, LP ("SK Capital") announced today that it has reached an agreement to sell NuCera Solutions ("NuCera" or the "Company") to Chase Corporation (NYSE American: CCF), a leading manufacturer of protective materials for high reliability applications.
AstraZeneca Announced Enhertu Approved in the EU for Patients With HER2-Positive Metastatic Breast Cancer Treated With One or More Prior Anti-HER2-based Regimens
July 19, 4:49 AM
Approval broadens indication for AstraZeneca and Daiichi Sankyo's Enhertu across Europe to earlier use in HER2-positive metastatic breast cancer. Based on ground-breaking DESTINY-Breast03 results in which Enhertu demonstrated a 72% reduction in the risk of disease progression or death vs. trastuzumab emtansine (T-DM1).
KKR Does Not Plan to Lead a Bid for Toshiba; Could Become Investor
July 19, 4:41 AM
-Reuters
https://www.reuters.com/article/toshiba-shareholders/kkr-has-no-plans-to-lead-a-toshiba-bid-could-become-an-investor-sources-idINL4N2YU1WO
Celcuity Announced FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer
July 18, 5:12 PM
Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today announced that the U.S.
Russian Court Fines Google 21B Roubles for Not Deleting Banned Content
July 18, 7:43 AM
-Reuters Citing Russian Affiliated News Agency RIA
Groupe Beneteau Launched Partnership With Vision Marine Technologies to Develop and Market 100% Electric Outboard-equipped Powerboats
July 18, 6:15 AM
Groupe Beneteau, a global market leader in recreational boating, and Vision Marine Technologies, the leader in electric transition of the recreational boating industry, have launched a partnership to integrate Vision Marine Technologies revolutionary, high-power outboard motors onboard several models across Groupe Beneteau's brand portfolio.